A 42-Year-Old Man Presents With Diarrhea

Poll

A 42-year-old man presents with diarrhea. After further evaluation, an intestinal biopsy is performed. What is your diagnosis?

A 42-year-old man presents with diarrhea. According to the slide image below, what is your diagnosis?

What is your diagnosis?

A. Histiocytic lymphoma
B. Whipple disease
C. Adenocarcinoma
D. Rhabdomyoma
Recent Videos
Alessio Pigazzi, MD, PhD, FACS, FASCRS, provides advice for upcoming surgeons starting out in the colorectal cancer field.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed how robot-assisted surgery for colorectal cancers has evolved over the past 20 years.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed surgical and medical oncology developments in the colorectal cancer field.
Related Content
Amivantamab Combo Reduces Symptom Progression in EGFR-Mutated NSCLC | Image Credit: © appledesign - stock.adobe.com.

Amivantamab Combo Reduces Symptom Progression in EGFR-Mutated NSCLC

Ariana Pelosci
September 11th 2024
Article

Patients with EGFR-mutated NSCLC had sustained HRQOL when treated with amivantamab plus lazertinib vs osimertinib.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Support for the planned biologics license application comes from data showing a 32.9% response rate with RP1 plus nivolumab for melanoma.

Pre-BLA Meeting Successful for RP1 Combo in Anti–PD-1–Failed Melanoma

Roman Fabbricatore
September 11th 2024
Article

Support for the planned biologics license application comes from data showing a 32.9% response rate with RP1 plus nivolumab for melanoma.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Community and academic oncologists discussed how effective communication between practices can enhance multiple myeloma outcomes.

Referrals From Community to Academia Enhances Multiple Myeloma Outcomes

Samer A. Al'Hadidi, MD;Frits van Rhee, MD, PhD;Appalanaidu Sasapu, MD
September 10th 2024
Article

Community and academic oncologists discussed how effective communication between practices can enhance multiple myeloma outcomes.

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Valemetostat Shows Meaningful Benefit in Peripheral T-Cell Lymphoma

Chris Ryan
September 10th 2024
Article

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.